{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-031065","form_type":"8-K","ticker":"MNPR","cik":"0001645469","company_name":"Monopar Therapeutics","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.924508+00:00","generated_at":"2026-06-08T06:51:30.860561+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monopar Q3 net loss improves to $2.0M; MNPR-101 radiopharma on track for first-in-human Dec 2023","bullets":["Net loss $2.0M ($0.14/share) vs $2.4M ($0.19) YoY; cash and equivalents $8.5M.","MNPR-101 radiopharma program to enter first-in-human study possibly as early as December 2023.","Camsirubicin Phase 1b at fifth dose cohort (650 mg/m^2); two patients showed tumor reductions of ~18% and 20%.","CTOS data: 9 of 14 stable disease, no DLT; one patient with LVEF decrease being assessed for cardiotoxicity.","Cash runway through November 2024; company expects to seek additional capital within 12 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-031065","json":"https://secwatch.observer/filing/0001437749-23-031065.json","markdown":"https://secwatch.observer/filing/0001437749-23-031065.md","text":"https://secwatch.observer/filing/0001437749-23-031065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923031065/0001437749-23-031065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923031065/mnpr20231030d_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:51:30.860561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28b75698ff8c6f8d6a40a67d1939b3d2c5a8b7c2","claim":"Monopar Therapeutics reported third quarter ended September 30, 2023 results: net income Net loss for the third quarter of 2023 was $2.0 million or $0.14 per share, EPS $0.14 per share.","evidence_excerpt":"Monopar Therapeutics Inc. issued a press release announcing its financial results and summarized recent developments for the third quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645469/000143774923031065/0001437749-23-031065-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss for the third quarter of 2023 was $2.0 million or $0.14 per share"},{"label":"EPS","value":"$0.14 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}